Report Scope:
This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.

Report Includes:

  • 45 data tables and 37 additional tables
  • An overview of the global markets for theranostics
  • Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
  • Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
  • Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
  • Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services
  • Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
  • A discussion of ESG challenges and ESG practices in the industry
  • Analysis of the key companies’ market shares, proprietary technologies and strategic alliances
  • Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.